SRR8613708
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.470
- TGF_BETA_SIGNALING+0.390
- HEDGEHOG_SIGNALING+0.380
- WNT_BETA_CATENIN_SIGNALING+0.360
- APICAL_SURFACE+0.300
- KRAS_SIGNALING_UP+0.280
- TNFA_SIGNALING_VIA_NFKB+0.220
- APICAL_JUNCTION+0.180
- NOTCH_SIGNALING+0.160
- MYOGENESIS+0.140
Top 10 suppressed
- E2F_TARGETS-0.540
- OXIDATIVE_PHOSPHORYLATION-0.500
- INTERFERON_ALPHA_RESPONSE-0.450
- DNA_REPAIR-0.420
- MTORC1_SIGNALING-0.420
- MYC_TARGETS_V1-0.420
- G2M_CHECKPOINT-0.390
- UNFOLDED_PROTEIN_RESPONSE-0.340
- MYC_TARGETS_V2-0.320
- PANCREAS_BETA_CELLS-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A2LM-01A-11R-A180-07 | — | A | 0.917 |
| 2 | TCGA-AR-A1AL-01A-21R-A12P-07 | — | A | 0.888 |
| 3 | TCGA-AC-A2FK-01A-12R-A180-07 | — | A | 0.865 |
| 4 | TCGA-E2-A1IO-01A-11R-A144-07 | — | A | 0.861 |
| 5 | TCGA-EW-A1IX-01A-12R-A144-07 | — | A | 0.855 |
| 6 | TCGA-D8-A145-01A-11R-A115-07 | — | A | 0.855 |
| 7 | TCGA-A7-A4SC-01A-12R-A266-07 | — | A | 0.853 |
| 8 | MBCProject_3896_T1_RNA | — | A | 0.849 |
| 9 | TCGA-B6-A0IH-01A-11R-A115-07 | — | A | 0.848 |
| 10 | TCGA-A2-A1G6-01A-11R-A13Q-07 | — | A | 0.845 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.470 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.390 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.380 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.300 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYOGENESIS | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.070 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.050 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.050 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.050 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.040 | Idelalisib | — uncovered |
| HYPOXIA | 0.030 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |